# US 2006/0040854 A1 · Prostate hyperplasia therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040854 A1
- Document ID: US20060040854A1
- Status: Published application
- Kind: A1
- Application number: 10/920,886
- Filed: 2004-08-17
- Published: 2006-02-23
- Earliest claimed: 2004-08-17
- Assignees: Board of Regents, The University of Texas System
- Inventors: Luis Parada
- Web page: https://patentgrep.com/patent/US20060040854A1

## CPC

- A61K 38/28: Insulins
- C07K 14/62: Insulins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method of determining whether a human patient determined to be subject to or predisposed to prostate hyperplasia patient underexpresses insulin-6, the method comprising the steps of: obtaining a biological sample from the patient and testing the sample for abnormal, insulin-6 underexpression expression relative to a control.

### Claim at position 3

10-11. (canceled)

### Claim 12 (depends on 9)

The method of claim 9 wherein the prostate hyperplasia is benign prostate hyperplasia (BPH).

### Claim 13 (depends on 9)

The method of claim 9 wherein the prostate hyperplasia is prostate cancer.

### Claim 14 (depends on 9)

The method of claim 9 wherein the patient is determined to be subject to the prostate hyperplasia.

### Claim 15 (depends on 9)

The method of claim 9 wherein the testing step detects an abnormally low level of insulin-6.

### Claim 16 (depends on 9)

The method of claim 9 wherein the testing step detects an abnormally low level of insulin-6, the patient is determined to be subject to the prostate hyperplasia, the method further comprising the step of prescribing to the patient an insulin-6 treatment regimen comprising contacting the patient with an effective amount of directly administered, exogenously produced insulin-6.

### Claim 17 (depends on 9)

The method of claim 9 wherein the testing step detects an abnormally low level of insulin-6, the patient is determined to be subject to the prostate hyperplasia, the method further comprising the step of prescribing to the patient an insulin-6 treatment regimen comprising contacting the patient with an effective amount of directly administered, exogenously produced insulin-6, and wherein after the prescribing step the method further comprises contacting the patient with insulin-6 pursuant the regimen.

### Claim 18 (depends on 9)

The method of claim 9 wherein the testing step detects an abnormally low level of insulin-6, the patient is determined to be subject to the prostate hyperplasia, the method further comprising the step of prescribing to the patient an insulin-6 treatment regimen comprising contacting the patient with an effective amount of directly administered, exogenously produced insulin-6, and wherein after the prescribing step the method further comprises contacting the patient with insulin-6 pursuant the regimen, and wherein after the contacting step, the method further comprises the step of detecting in the patient a reduction in growth or size the prostate hyperplasia.
